PUBLISHER: Grand View Research | PRODUCT CODE: 1609979
PUBLISHER: Grand View Research | PRODUCT CODE: 1609979
The global sickle cell anemia testing and screening market size is expected to reach USD 829.5 million by 2030, expanding at a CAGR of 12.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Hemoglobin S (HbS) is the causative factor for sickle cell disease and is currently the most prevailing disease or genetic abnormality across the globe, specifically across developing economies.
Sickle cell hemoglobin variants are inclusive of HbS, HbA, and HbC. Different tests have been developed to perform a clear distinction between all the three above-mentioned hemoglobin variants. Development of a deep learning framework designed to perform automated screening of sickle cell anemia in blood smear sample of patients via a smartphone microscope is set to open up new avenues for the market in the near future.
The market is moderately consolidated, wherein the key industry participants are striving to sustain market competition via partnerships, acquisitions, and expanding their business across newborn testing market space. Whereas, emerging companies are exploring potential of point-of-care tests to gain a competitive edge in the market.
A steep increase in the uptake of Hb electrophoresis and HPLC across government-initiated newborn screening programs and assessment studies have resulted in robust market penetration. This has, in turn, caught the attention of companies who are keen on modifying their existing product line, further amplifying consumption of the same.